<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1044">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04587323</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300005378</org_study_id>
    <nct_id>NCT04587323</nct_id>
  </id_info>
  <brief_title>VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease</brief_title>
  <official_title>COVID-19 RELATED SUBMISSION: VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial&#xD;
      permeability and contribute to multi-organ injury in patients with COVID-19 disease and to&#xD;
      correlate the levels of these mediators with disease outcomes such as ICU admission, length&#xD;
      of ventilatory support, respiratory failure, kidney failure, heart failure, and death.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      When patients are sick with other lung infections (pneumonias) caused by viruses or bacteria&#xD;
      there are changes in a pathway that regulates the &quot;leakiness&quot; the tiny airspaces inside the&#xD;
      lungs. Even bigger changes in this pathway are seen when patients develop severe breathing&#xD;
      difficulties (acute respiratory distress syndrome) similar to what is seen in patients who&#xD;
      get really sick with COVID-19 disease.&#xD;
&#xD;
      There are important changes in this pathway that occur in patients who have preexisting&#xD;
      cardiovascular (heart) disease who do not have lung infections. The investigator will&#xD;
      evaluate these levels in patients with COVID-19 because the investigator believes that this&#xD;
      baseline difference in pathway regulation may be one reason patients with heart disease who&#xD;
      contract COVID-19 get sicker than patients without heart or vascular disease.&#xD;
&#xD;
      The investigator will also assess the levels of components of this pathway in patients who&#xD;
      are less sick with those who became sick enough to require a tube to help them breathe&#xD;
      because this is important to determine if COVID-19 lung disease has a similar effect on this&#xD;
      pathway as other lung infections like flu and bacterial pneumonias.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 22, 2020</start_date>
  <completion_date type="Anticipated">May 20, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 20, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Laboratory Assays</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>The primary outcome measure is the ratio of soluble fms-like tyrosine kinase receptor-1 (sFlt-1) to vascular endothelial growth factor (VEGF) which will be obtained using an immunoassay on blood samples. The specimens will be analyzed using enzyme-linked immunosorbent assay and reported as a ratio</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-A</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>Plasma samples will be analyzed to measure VEGF-A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-C</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>Plasma samples will be analyzed to measure VEGF-C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VEGF-D</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>Plasma samples will be analyzed to measure VEGF-D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tie-2</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>Plasma samples will be analyzed to measure Tie-2</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flt-1</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>Plasma samples will be analyzed to measure Flt-1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PlGF</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>Plasma samples will be analyzed to measure PlGF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>FGF</measure>
    <time_frame>7-14 days after symptom onset</time_frame>
    <description>Plasma samples will be analyzed to measure FGF</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID-19 Disease</condition>
  <arm_group>
    <arm_group_label>Group 1:</arm_group_label>
    <description>Group 1: COVID-19 + inpatients who did not require mechanical ventilation (25 patients);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2:</arm_group_label>
    <description>Group 2: COVID-19 + inpatients who required mechanical ventilation (25 patients).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3:</arm_group_label>
    <description>Group 3: COVID-19 + inpatients with no preexisting cardiovascular disease (25 patients)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4:</arm_group_label>
    <description>Group 4: COVID-19 + inpatients with preexisting cardiovascular disease (25 patients).</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      We will identify patients with COVID-19 disease within the CCTS Biorepository with a blood&#xD;
      (plasma) sample from within 7-14 days of symptom onset&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who have available specimens in the UAB CCTS Biorepository for COVID-19 patients.&#xD;
        (IRB-300005127: COVID-19 Enterprise Biorepository.)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive test for COVID-19 (SARS-CoV-2 infection)&#xD;
&#xD;
          -  &gt;=18 years&#xD;
&#xD;
          -  Blood (plasma) specimen(s) available in the CCTS biorepository&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  &lt;18 years&#xD;
&#xD;
          -  Lack of blood specimen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dylan Addis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dylan Addis, MD</last_name>
    <phone>919-812-5107</phone>
    <email>dylanaddis@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Shanna H Graves</last_name>
    <phone>205-975-2845</phone>
    <email>shannagraves@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dylan Addis, MD</last_name>
      <phone>919-812-5107</phone>
      <email>dylanaddis@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Shanna H Graves</last_name>
      <phone>205-975-2845</phone>
      <email>shannagraves@uabmc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 14, 2020</study_first_posted>
  <last_update_submitted>October 13, 2020</last_update_submitted>
  <last_update_submitted_qc>October 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Dylan R. Addis, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>SARS-CoV-2 viral infection</keyword>
  <keyword>VEGF and sFlt-1 levels</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

